Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company pioneering iPSC-derived cell therapies for cancer and autoimmune diseases. This page provides investors and industry observers with direct access to the company's official announcements, including clinical trial progress, financial results, and strategic collaborations.
Our curated news collection enables efficient tracking of material developments in IPSC's Allo-Evasion™ platform and pipeline candidates like CNTY-101. Users will find press releases covering FDA submissions, partnership agreements with leading research institutions, and presentations at major medical conferences.
Key updates include quarterly earnings reports, manufacturing advancements, intellectual property milestones, and peer-reviewed data publications. All content is sourced directly from Century Therapeutics' investor relations communications to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of IPSC's progress in developing off-the-shelf cell therapies. Check regularly for updates on preclinical achievements, IND applications, and corporate developments shaping the future of regenerative medicine.
Century Therapeutics (NASDAQ: IPSC) has announced a live fireside chat scheduled for Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss their prioritized preclinical cell therapy programs. The event will showcase three key investigational therapies:
- CNTY-308: A CD19-targeted CAR-iT cell therapy
- CNTY-341: A CD19/CD22 dual-targeted CAR-iT cell therapy
- A solid tumor CAR iT program focusing on Nectin-4 CAR and other validated targets
All programs utilize advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and incorporate the company's proprietary Allo-Evasion™ 5.0 technology, designed for comprehensive immune evasion. The presentation will also explore the potential expansion of their selective iPSC differentiation expertise to non-immune effector cells. The event will be accessible through Century's website, with a replay available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC) announced a strategic pipeline re-prioritization focusing on four key programs, led by CNTY-308 for B-cell mediated autoimmune diseases. The company reported a strong financial position with $220.1M in cash as of December 31, 2024, extending runway into Q4 2026.
Key developments include:
- Early discontinuation of ELiPSE-1 trial in NHL
- First patient enrollment in CALiPSO-1 Phase 1 trial scheduled for March 2025
- CARAMEL investigator-initiated trial expected to commence mid-2025
- Expansion of CALiPSO-1 trial sites in US and Europe
Financial highlights for 2024:
- Net loss: $126.6M (improved from $136.7M in 2023)
- R&D expenses: $107.2M (up from $92.7M in 2023)
- G&A expenses: $33.2M (down from $34.7M in 2023)
- Collaboration revenue: $6.6M from Bristol-Myers Squibb partnership
Century Therapeutics (NASDAQ: IPSC) has announced a Phase 1/2 investigator-initiated trial (IIT) of its CD19 CAR-iNK cell therapy candidate CNTY-101 for B-cell mediated autoimmune diseases. The trial, known as CARAMEL, will be led by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.
The study will evaluate CNTY-101's safety, efficacy, and translational data in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis. This represents the first evaluation of an allogeneic iPSC-derived CD19-directed NK cell therapy for autoimmune diseases by the Schett/Mackensen group.
The CARAMEL trial is scheduled to begin in mid-2025 pending CTA approval. Additionally, Century plans to expand its ongoing Phase 1 CALiPSO-1 trial to include European sites.
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The company will be represented in two events: an Autoimmune Disease Cell Therapy Panel at 3:00 PM ET featuring CSO Chad Cowan, and a Fireside Chat at 4:30 PM ET with CEO Brent Pfeiffenberger and CSO Chad Cowan. A live webcast of the fireside chat will be available on the company's website with a 90-day replay option.
Century Therapeutics (NASDAQ: IPSC) reported Q3 2024 financial results and business updates. Key highlights include an 83% overall response rate for CNTY-101 at Dose Level 3B in B-cell lymphomas, and expansion of the Phase 1 CALiPSO-1 trial to include new autoimmune indications. The company ended Q3 with $244.7 million in cash and investments, extending runway into H2 2026. Q3 net loss was $31.2 million, with R&D expenses at $27.2 million. The company expects full-year GAAP operating expenses between $150-160 million. Following organizational restructuring, Century plans to announce results of its pre-clinical pipeline strategic review in Q1 2025.
Century Therapeutics (NASDAQ: IPSC) announced it will present preclinical data from its iPSC-derived cell therapy platform in five posters at the 2024 ASH Annual Meeting. The presentations will showcase advances in their iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune diseases. Key highlights include the development of iPSC-derived CD4+ and CD8+ CAR T cells with functionality comparable to primary αβ CAR-T cells, enhanced Allo-Evasion™ technology, and data demonstrating CAR iNK and γδ iT cells' potential in treating B-cell-mediated autoimmune diseases. The meeting will be held in San Diego from December 7-10, 2024.
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on developing iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Brent Pfeiffenberger and CSO Chad Cowan will engage in a fireside chat on November 12, 2024, at 9:30am ET. The presentation will be accessible via live webcast on the company's investor relations website, with replay available for 90 days post-event.
Century Therapeutics (NASDAQ: IPSC) has announced key leadership changes, effective October 2024. Morgan Conn, Ph.D., has been appointed as Chief Financial Officer, bringing over 20 years of financing and business development experience in biopharma. Chad Cowan, Ph.D., a cell therapy pioneer and founder of Clade Therapeutics, will serve as Chief Scientific Officer. Both will join the Executive Committee.
The company also announced that Hy Levitsky, M.D., President of Research and Development, will transition to an advisory role. These appointments come at a important time as Century advances its clinical programs, expands into autoimmune indications, and accelerates prioritized next-generation pipeline programs.
Century Therapeutics specializes in developing induced pluripotent stem cell (iPSC)-derived cell therapies for immuno-oncology and autoimmune diseases. The company's focus includes iNK, γδ iT, and αβ iT-cell programs, combined with its Allo-Evasion™ technology.
Century Therapeutics (NASDAQ: IPSC) reported Q2 2024 financial results and business updates. Key highlights include:
1. Initiation of Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, expanding into autoimmune diseases.
2. Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101, showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas.
3. Completed dose escalation for ELiPSE-1, advancing to dose expansion in 2H 2024.
4. Q2 2024 ended with $269.6 million in cash, cash equivalents, and investments.
5. Net loss of $31.2 million for Q2 2024.
6. Full-year GAAP operating expenses expected between $150-160 million.
7. Cash runway extended into 2026.
Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study at the ASCO 2024 Annual Meeting. The study evaluates CNTY-101, an iPSC-derived NK cell therapy, in patients with relapsed or refractory non-Hodgkin lymphoma. CNTY-101 demonstrated a manageable safety profile with no dose-limiting toxicities or graft-versus-host disease and showed encouraging preliminary efficacy. The trial's novel cell-free DNA method indicates CNTY-101 persists outside the bloodstream. The study continues with dose escalation at higher levels, aiming to further validate safety and efficacy.
